Sleep & breathing · graded by use, two uses
Hypoglossal nerve stimulation for obstructive sleep apnea
Apnea-hypopnea index and Epworth sleepiness in implanted adults with moderate to severe sleep apnea who cannot use CPAP.
At a glance
Hypoglossal nerve stimulation is an implant, like a pacemaker, that moves the tongue forward during sleep. In people who could not use CPAP, it cut breathing pauses and daytime sleepiness against a switched-off device. In one study it did not lower blood pressure.
The B belongs to one of the two uses graded on this record. The other one carries its own letter.
As studied, and the trials
In a sham-controlled crossover of 89 implanted adults, stimulation lowered the apnea-hypopnea index by 15.5 events an hour and Epworth scores by 3.3 points (Heiser et al., J Clin Med, 2021; PMID 34209581). A second device, tested by delayed activation in 104 adults, met its response definition in 58 percent against 14 percent (Malhotra et al., Ann Intern Med, 2026; PMID 42008810), and switching therapy off returned breathing to baseline (Woodson et al., Otolaryngol Head Neck Surg, 2014; PMID 25205641). The trials were run with or funded by the device makers. Surrogate and self-reported outcomes cap the letter at B.
As studied, and the trials
A double-blind sham-controlled crossover in 60 implanted adults found no difference in 24-hour systolic pressure (0.18 mmHg) or in vascular function (Dedhia et al., JAMA Otolaryngol Head Neck Surg, 2024; PMID 38032624). One trial, null and unrepeated: C.
Read the grade that matches your goal. How EBL grades by use →
A letter describes the human evidence, not the product, the manufacturer, or the intervention's worth.
See the full evidence record →Graded on Apnea severity and daytime sleepiness in implanted adults who cannot use CPAP.
Why this letter
Why this gradeThe reasoning, and what the grade does not cover.
Grade B on apnea severity and Epworth sleepiness in implanted adults who cannot use CPAP, from a sham-controlled crossover (Heiser et al., 2021; PMID 34209581), a delayed-activation trial of a second device (Malhotra et al., 2026; PMID 42008810) and a withdrawal trial (Woodson et al., 2014; PMID 25205641), each run with or funded by the device maker. Grade C on blood pressure: one sham-controlled crossover was null (Dedhia et al., 2024; PMID 38032624).
WHY NOT Asurrogate and self-reported outcomes.
WHAT THIS GRADE DOES NOT COVERpeople with a body mass index above the trials' range of about 28 to 31, people with central sleep apnea, people who can use CPAP, and cardiovascular events, which no cited trial measured.
A grade describes the human evidence for a named use. It is not advice, and it is not a judgment on any individual prescription. How the letters are decided →
Evidence notes: randomized trial
Endpoint The outcome a trial measures to decide whether the treatment worked, such as heart attacks, blood pressure or a symptom score. graded: Apnea severity and daytime sleepiness in implanted adults who cannot use CPAP (surrogate)
Last reviewed: October 2026
The trial that would change this grade.
Positive trials of this shape from independent research groups would move this entry to A.
Why the current trials fall short
The trials so far measured breathing counts and a questionnaire, and the blood pressure use rests on one null 4-week crossover.
Dose, form and timing
Apnea-hypopnea index on a titration or home study with the device on, nightly hours of use, and the Epworth Sleepiness Scale.
Safety
Requires surgery to implant. Tongue soreness and discomfort from stimulation are reported, and central sleep apnea can limit the response.
Grade history
How this letter has changedLatest: No. 366 · October 2026 · First graded.
The implanted tongue-nerve stimulator now has a record. Against sham stimulation it cut breathing pauses and sleepiness (Heiser et al., J Clin Med, 2021; PMID 34209581), repeated with a second device (Malhotra et al., Ann Intern Med, 2026; PMID 42008810): Grade B. Blood pressure did not change in a sham-controlled crossover (Dedhia et al., JAMA Otolaryngol Head Neck Surg, 2024; PMID 38032624): Grade C.PMID 34209581 PMID 42008810 PMID 38032624
Every change to a letter on this site is dated and published. The full evidence log →
Sources
- Citations
- Every paper cited on this page is matched to its PubMed record on every build.
- Retractions
- None of these papers is retracted or under a journal expression of concern. PubMed is checked again on every build.
- Read against the papers
- October 2026. By a language model (AI-assisted reading), not yet reviewed by a clinician.
- Outside review
- Not yet done. No reviewer outside EBL has checked this record.
What each of these checks can and cannot show: evidence integrity.
Primary evidenceFive papers, each linked to its PubMed record.
Heiser et al. (J Clin Med, 2021; PMID 34209581): EFFECT, sham-controlled randomized crossover, 89 patients. Malhotra et al. (Ann Intern Med, 2026; PMID 42008810): OSPREY, 104 patients randomized 2:1 to early or delayed activation, unblinded, funded by the device maker. Woodson et al. (Otolaryngol Head Neck Surg, 2014; PMID 25205641): randomized therapy withdrawal in 46 responders. Strollo et al. (N Engl J Med, 2014; PMID 24401051): STAR, a single-group cohort of 126 implanted patients, shown as context and not counted toward the letter. Dedhia et al. (JAMA Otolaryngol Head Neck Surg, 2024; PMID 38032624): sham-controlled crossover on blood pressure, null.
Evidence Based Longevity, Inc. is owner-operated and edited by Arnold Sandlow, D.C., a California-licensed chiropractor. Evidence Based Longevity publishes in English only · Machine translations are not produced or reviewed by EBL for accuracy
How EBL searched for the trials (1 search)
The search that was run, what it returned, and what was left out and why, so the absence of evidence can be checked as well as its presence.
("hypoglossal nerve stimulation"[tiab] OR "upper airway stimulation"[tiab]) AND (randomized controlled trial[pt] OR randomized[tiab])Disclosure
Educational use only · Not medical advice · EBL grades published human evidence and does not recommend treatment. Stopping a prescription is a decision for your physician.
This page carries a letter. No letter has been bought and none is for sale. Products listed under this modality may be commercial partners, and their purchase links may earn EBL a commission. Those products carry no letter of their own, every relationship is disclosed beside the link, and where a product does not deliver what the trials tested, this page says so regardless of who pays.
How this is enforced
That is not a promise, it is a build condition. Two checks run on every deploy: one refuses to publish if a page says EBL earns a commission on anything that carries a letter, the other refuses if a page names a commercial relationship that is not declared in the register. If either fails, this page does not go live. You can read how the checks work, and what they do not cover, on the evidence integrity page.
© Evidence Based Longevity, Inc.. All rights reserved
These statements have not been evaluated by the Food and Drug Administration. Any grade on this page describes the strength of published human trial evidence in the populations studied. It is not a recommendation for any individual and is not medical advice. Starting, stopping or changing any supplement or medication is a decision for your physician.
Grades move when new trials publish. A free monthly email lists every grade EBL moved, with the reason and the trial behind it: the sign-up is on the Evidence Log →